The results come as Lilly continues to test Sofe-M in different types of ovarian cancer, with multiple Phase 3 trials now ...

Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with ...

Eli Lilly has shared phase 1 data on an antibody-drug conjugate (ADC) in platinum-sensitive ovarian cancer (PSOC), shedding ...

Lilly's sofetabart mipitecan achieves 79% response rate in platinum-sensitive ovarian cancer patients, including those with prior PARP inhibitor exposure.

Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity ...

Eli Lilly and Company announced new Phase 1 data showing that its investigational folate receptor alpha (FRa) antibody-drug conjugate (ADC) sofetabart mipitecan (Sofe-M) plus bevacizumab achieved a ...

Eli Lilly (LLY) stock fell 2.54% despite Sofe-M posting a 79.3% response rate in Phase 1 ovarian cancer trials, as the drug ...

The genius dystopian gem V for Vendetta, starring Hugo Weaving, is proving popular on the global HBO Max charts.

Healthcare ETFs are hovering near 52-week highs as earnings prospects improve, clinical breakthroughs advance and GLP-1 demand expands. Explore five ETFs riding the rally.

Moderator Ricardo Costa, MD, MSc, led colleagues from Moffitt Cancer Center in the first panel, “Targeted Success: ...

Registrational Phase 3 G-HOPE-001 Study Met Both Primary Endpoints, Demonstrating Statistically Significant and Clinically ...

Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical ...